1Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press,2001.61-73.
2O' Connell J, Bennett MW, O' Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today, 1999,20:46-52.
3Lepelley P, Grardel N, Erny O, et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma, 1998,30:307-312.
4Kitagawa M, Yamaguchi S, Takahashi M, et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia.Leukemia, 1998,12:486-492.
5Paul P, Rouas-Freiss N, Khalil-Daher I,et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance .Proc Natl Acad Sci U S A, 1998,95:4510-4515.
6Carosella ED, Rouas-Freiss N, Paul P, et al. HLA-G: a tolerance molecule from the major histocompatibility complex. Immonol Today,1999,20:60-62.
7Brouwer RE, van der Heiden P, Schreuder GM,et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol,2002, 63:200-210.
8Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Eng J Med, 1999,342:1351-1358.
9Norgaard P, Hougaard S, Poulsen HS, et al. Transforming growth factor β and cancer. Cancer Treat Rev,1995,21:367-403.
10Allampallam K, Shetty V, Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol, 2002,75:289-297.
